BofA Securities analyst Alec Stranahan initiates coverage on $Intellia Therapeutics (NTLA.US)$ with a buy rating, and sets the target price at $65.
According to TipRanks data, the analyst has a success rate of 50.5% and a total average return of -2.6% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Intellia Therapeutics (NTLA.US)$'s main analysts recently are as follows:
Following the presentation of Phase 2 data for NTLA-2002, which indicated a reduction in attack rates that was perceived as less notable compared to earlier Phase 1 results for HAE, expectations for the treatment's market share peak have been moderated. Despite this, the unique 'one-and-done' administration of NTLA-2002 remains a key differentiator from other treatments requiring more frequent dosing. The market opportunity for NTLA-2002 continues to be seen as competitive, but anticipations have been tempered due to revised success probabilities for NTLA-2001 in ATTR, pending further validation of the platform.
The perspective on Intellia Therapeutics has become incrementally negative after evaluating the Phase 2 study of NTLA-2002 in patients with hereditary angioedema (HAE).
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美銀證券分析師Alec Stranahan首次給予$Intellia Therapeutics (NTLA.US)$買入評級,目標價65美元。
根據TipRanks數據顯示,該分析師近一年總勝率為50.5%,總平均回報率為-2.6%。
此外,綜合報道,$Intellia Therapeutics (NTLA.US)$近期主要分析師觀點如下:
鑑於NTLA-2002的2期數據表明,相對於HAE的早期1期結果,攻擊率下降的情況被認爲不太顯著,治療市場份額峯值預期已經有所降溫。儘管如此,NTLA-2002的獨特的「一次永久」管理方式仍然是與其他需要更頻繁服用的治療方法的主要區別。NTLA-2002的市場機會仍然被視爲競爭激烈,但由於NTLA-2001在ATTR中的修訂後成功概率和平台的進一步驗證待定,人們對其預期已有所降溫。
在評估NTLA-2002在患有遺傳性血管性水腫(HAE)患者中的2期研究後,對Intellia Therapeutics的看法逐漸變得負面。
提示:
TipRanks為獨立第三方,提供金融分析師的分析數據,並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議,僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級,分析師星級代表分析師所有推薦的過往表現,通過分析師的總勝率和平均回報率综合計算得出,星星越多,則該分析師過往表現越優異,最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否,取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合,並根據評級變化對組合進行調整,在近一年中該投資組合所獲得的回報率。